DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus recommendation of “Moderate Buy” by the eighteen analysts that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $98.00.

DXCM has been the topic of several recent analyst reports. Wells Fargo & Company upped their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Raymond James cut their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Canaccord Genuity Group upped their price objective on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Sanford C. Bernstein boosted their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DexCom

Hedge funds have recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. lifted its position in shares of DexCom by 4.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after buying an additional 162 shares during the last quarter. Sachetta LLC increased its position in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the period. Crossmark Global Holdings Inc. raised its stake in shares of DexCom by 1.0% during the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after purchasing an additional 182 shares in the last quarter. Perennial Investment Advisors LLC lifted its stake in shares of DexCom by 7.4% in the 2nd quarter. Perennial Investment Advisors LLC now owns 3,156 shares of the medical device company’s stock worth $358,000 after acquiring an additional 217 shares during the period. Finally, Riverview Trust Co increased its stake in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 2.9 %

DexCom stock opened at $77.76 on Wednesday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market cap of $30.37 billion, a PE ratio of 46.56, a price-to-earnings-growth ratio of 2.36 and a beta of 1.12. The stock’s 50 day moving average price is $76.93 and its 200 day moving average price is $78.84.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.